secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000805928-23-000087
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M
--------------------------------------------------------------

- Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.
- Net loss $6.7M ($0.16 per share) vs $7.7M loss a year ago; adjusted net loss $1.3M ($0.03 per share).
- Gross margin 81.1% (vs 81.8% YoY); cash & investments $40.8M; $3.6M capex for new Dayton processing facility.
- FY 2023 revenue guidance maintained at $154M-$159M (11-15% growth); gross margin expected ~80% for full year.
- Pilot launched Axoguard HA+ Nerve Protector; BLA submission for Avance expected Q1-Q2 2024 with target approval H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/0000805928-23-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000087/axgn-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000805928-23-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer